Erik Duijvelaar

5PUBLICATIONS
21CO-AUTHORS
Medical devicesRespiratory diseasesMolecular targetsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 25, 2026
Empagliflozin Ameliorates Experimental Pulmonary Vascular Remodeling, but May Not Benefit Patients With Pulmonary Arterial Hypertension.

|Oct 22, 2024
Deep phenotyping of pulmonary edema and pulmonary vascular permeability in COVID-19 ARDS.

Job R Schippers, Leila N Atmowihardjo, Erik Duijvelaar

|Feb 29, 2024
Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial.

Erik Duijvelaar, Xiaoke Pan, Harm Jan Bogaard

|Jan 25, 2024
Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients.

Erik Duijvelaar, Jack Gisby, James E Peters

|Jul 27, 2022
Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.

Justin de Brabander, Erik Duijvelaar, Job R Schippers

Pageof 1

Frequent Collaborators

5 joint publications

Harm-Jan Bogaard

4 joint publications

Jurjan Aman

2 joint publications

Lieuwe D J Bos

1 joint publications

Hessel Peters-Sengers